sur Theralase Technologies Inc. (isin : CA88337V1004)
Theralase Successfully Destroys Lung Cancer
Theralase Technologies Inc. (TSXV:TLT) has announced a significant breakthrough in the preclinical treatment of Non-Small Cell Lung Cancer (NSCLC). The company's lead compound, Rutherrin®, has shown promising results in preclinical experiments using a Lewis Lung Cancer (LLC1) orthotopic model.
In the experiments, Rutherrin® exhibited a higher retention rate in lung tumors compared to normal lung tissues. This enhanced selectivity improved the compound's effectiveness in targeting lung cancer. All animals treated with x-ray activated Rutherrin® survived, in contrast to those that received only x-ray treatment.
Tumor progression was significantly slower in mice treated with Rutherrin®, with some cases showing tumor regression. Theralase plans to initiate a Phase Ia clinical study for patients with GBM and NSCLC in 4Q2024, potentially expanding to other cancers such as pancreatic, prostate, kidney, and colorectal cancer pending sufficient capital.
R. H.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theralase Technologies Inc.